Aptamers are small DNA, RNA, or peptide fragments that are engineered to bind to specific targets – small molecules, large biomolecules, and even cells. Aptamers are often referred to as “synthetic” antibodies. Since their advent in 1990, Aptamers have been developed for use in diagnostics.
Aptamers for D-Dimer
Aptamers specific to the D-Dimer series of FDPs have been published in a patent (US 20140296500 A1, Pub. date: Oct 2, 2014), but the development of the testing platform and validation of the diagnostic protocol is done first time by Aptamer Diagnostic.
The inherent high affinity, specificity, biochemical stability, low to absent immunogenicity, fast production, and relatively low cost of production makes Aptamers very desirable as substitutes for antibodies in diagnostics and future therapeutic applications.